Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 695,342
  • Shares Outstanding, K 47,270
  • Annual Sales, $ 1,540 K
  • Annual Income, $ -135,750 K
  • 36-Month Beta 0.87
  • Price/Sales 6.58
  • Price/Cash Flow N/A
  • Price/Book 6.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.35 +2.51%
on 01/02/18
15.86 -7.25%
on 01/04/18
-0.77 (-4.97%)
since 12/19/17
3-Month
14.07 +4.55%
on 11/14/17
18.39 -20.01%
on 11/01/17
-3.07 (-17.27%)
since 10/19/17
52-Week
8.58 +71.45%
on 03/07/17
20.25 -27.36%
on 10/02/17
+5.18 (+54.35%)
since 01/19/17

Most Recent Stories

More News
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

-- Phase 3 Study of Non-Dialysis Patients in Japan Ongoing; Phase 3 Studies of Dialysis Patients to Begin in 2018 --

AKBA : 14.71 (+0.34%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.71 (+0.34%)
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

AKBA : 14.71 (+0.34%)
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

AERI : 59.30 (+2.42%)
AKBA : 14.71 (+0.34%)
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

SGMO : 18.90 (+6.48%)
SRPT : 63.24 (+1.38%)
AKBA : 14.71 (+0.34%)
CALA : 8.40 (+0.60%)
GLYC : 23.59 (+8.46%)
5 Top-Ranked Drug Stocks that are Broker Favorites

With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

SGMO : 18.90 (+6.48%)
SRPT : 63.24 (+1.38%)
AKBA : 14.71 (+0.34%)
INCY : 93.16 (+1.35%)
CALA : 8.40 (+0.60%)
PFE : 36.90 (-0.11%)
GLYC : 23.59 (+8.46%)
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

CNCE : 19.61 (-0.51%)
AKBA : 14.71 (+0.34%)
Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.71 (+0.34%)
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%

GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.

AKBA : 14.71 (+0.34%)
GLYC : 23.59 (+8.46%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.71 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 15.08
1st Resistance Point 14.90
Last Price 14.71
1st Support Level 14.52
2nd Support Level 14.32

See More

52-Week High 20.25
Fibonacci 61.8% 15.79
Last Price 14.71
Fibonacci 50% 14.41
Fibonacci 38.2% 13.04
52-Week Low 8.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.